File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes

TitleLower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Authors
Keywordsanti-diabetic drugs
cohort study
crystalline arthropathy
diabetes mellitus
DPP4
gout
metabolic syndrome
mortality
retrospective study
SGLT2
Issue Date2023
Citation
Rheumatology (United Kingdom), 2023, v. 62, n. 4, p. 1501-1510 How to Cite?
AbstractObjectives: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks. Methods: This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 in Hong Kong. The study outcomes are new-onset gout and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I was performed. Univariable and multivariable Cox regression models were conducted. Competing risks models and multiple approaches based on the propensity score were applied. Results: This study included 43 201 patients [median age: 63.23 years old (Interquartile range, IQR): 55.21–71.95, 53.74% males; SGLT2I group: n ¼ 16 144; DPP4I group: n ¼ 27 057] with a median follow-up of 5.59 years (IQR: 5.27–5.81 years) since initial drug exposure. The incidence rate of developing gout [Incidence rate (IR): 2.5; 95% CI: 2.2, 2.9] among SGLT2I users was significantly lower than DPP4I users (IR: 5.2; 95% CI: 4.8, 5.8). SGLT2I was associated with 51% lower risks of gout (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) and 51% lower risks of all-cause mortality (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory results. The results remained consistent on competing risk and other propensity score approaches. Conclusions: SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use.
Persistent Identifierhttp://hdl.handle.net/10722/330300
ISSN
2023 Impact Factor: 4.7
2023 SCImago Journal Rankings: 1.721
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhou, Jiandong-
dc.contributor.authorLiu, Xuejin-
dc.contributor.authorChou, Oscar Hou In-
dc.contributor.authorLi, Lifang-
dc.contributor.authorLee, Sharen-
dc.contributor.authorWong, Wing Tak-
dc.contributor.authorZhang, Qingpeng-
dc.contributor.authorChang, Carlin-
dc.contributor.authorLiu, Tong-
dc.contributor.authorTse, Gary-
dc.contributor.authorJing, Fengshi-
dc.contributor.authorCheung, Bernard Man Yung-
dc.date.accessioned2023-09-05T12:09:22Z-
dc.date.available2023-09-05T12:09:22Z-
dc.date.issued2023-
dc.identifier.citationRheumatology (United Kingdom), 2023, v. 62, n. 4, p. 1501-1510-
dc.identifier.issn1462-0324-
dc.identifier.urihttp://hdl.handle.net/10722/330300-
dc.description.abstractObjectives: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks. Methods: This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I between 1 January 2015 and 31 December 2020 in Hong Kong. The study outcomes are new-onset gout and all-cause mortality. Propensity score matching (1:1 ratio) between SGLT2I and DPP4I was performed. Univariable and multivariable Cox regression models were conducted. Competing risks models and multiple approaches based on the propensity score were applied. Results: This study included 43 201 patients [median age: 63.23 years old (Interquartile range, IQR): 55.21–71.95, 53.74% males; SGLT2I group: n ¼ 16 144; DPP4I group: n ¼ 27 057] with a median follow-up of 5.59 years (IQR: 5.27–5.81 years) since initial drug exposure. The incidence rate of developing gout [Incidence rate (IR): 2.5; 95% CI: 2.2, 2.9] among SGLT2I users was significantly lower than DPP4I users (IR: 5.2; 95% CI: 4.8, 5.8). SGLT2I was associated with 51% lower risks of gout (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) and 51% lower risks of all-cause mortality (HR: 0.49; 95% CI: 0.42, 0.58; P-value < 0.0001) after adjusting for significant demographics, past comorbidities, medications and laboratory results. The results remained consistent on competing risk and other propensity score approaches. Conclusions: SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use.-
dc.languageeng-
dc.relation.ispartofRheumatology (United Kingdom)-
dc.subjectanti-diabetic drugs-
dc.subjectcohort study-
dc.subjectcrystalline arthropathy-
dc.subjectdiabetes mellitus-
dc.subjectDPP4-
dc.subjectgout-
dc.subjectmetabolic syndrome-
dc.subjectmortality-
dc.subjectretrospective study-
dc.subjectSGLT2-
dc.titleLower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/rheumatology/keac509-
dc.identifier.pmid36066415-
dc.identifier.scopuseid_2-s2.0-85152156931-
dc.identifier.volume62-
dc.identifier.issue4-
dc.identifier.spage1501-
dc.identifier.epage1510-
dc.identifier.eissn1462-0332-
dc.identifier.isiWOS:000859211900001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats